Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Will The Nontuberculous Mycobacterial Infection Market Valuation Change Between Now And 2029?

In recent times, there has been a consistent increase in the market size for nontuberculous mycobacterial infection. It’s projected to escalate from $14.25 billion in 2024 to $14.96 billion in 2025, representing a compound annual growth rate (CAGR) of 5.0%. The augmentation during the historic period is attributed to enhancements in diagnostics, an aging demographic, increased awareness of cystic fibrosis, and immunosuppressive drugs.

The market for nontuberculous mycobacterial infection is projected to witness robust growth in the upcoming years, expanding to a value of $19.37 billion by 2029, with a compound annual growth rate (CAGR) of 6.7%. The growth during this forecast period is likely due to factors such as the progression in antimicrobial drug research, heightened understanding of ntm, advancements in genetic studies, as well as the utilization of telehealth and remote monitoring. Personalized treatment, regulatory emphasis, combination treatments, and digital health tools are major trends expected during this forecast period.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13020&type=smp

What Underlying Factors Are Supporting The Nontuberculous Mycobacterial Infection Market Growth?

The nontuberculous mycobacterial infection market is anticipated to expand due to the growing occurrence of chronic obstructive pulmonary disease (COPD). COPD, a lasting respiratory illness, is typified by constant and typically worsening constraints to airflow in the lungs. More significant reductions in forced expiratory volume in one second (FEV1) and a heightened rate of exacerbation are related to nontuberculous mycobacterial (NTM) infections in individuals with COPD. The immune system may become weakened and lung tissue can be damaged due to COPD, making it simpler for NTM bacteria to infect the lungs. The Scottish Public Health Observatory (ScotPHO) reported in March 2023 that COPD rates had started to increase from 2021 to 2022. The rates rose among males from 83.2 to 97.6 per 100,000 people while female rates rose from 72.6 to 97.3. The nontuberculous mycobacterial infection market is therefore being propelled by the escalating prevalence of chronic obstructive pulmonary disease (COPD).

Which Sub-Segments Are Driving Growth Within The Nontuberculous Mycobacterial Infection Market?

The nontuberculous mycobacterial infectionmarket covered in this report is segmented –

1) By Drug Class: Macrolides; Rifampin; Aminoglycoside; Other Drug Classes

2) By Route Of Administration: Oral; Parenteral; Other Routes

3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Subsegments:

1) By Macrolides: Azithromycin; Clarithromycin

2) By Rifampin: Rifampin; Rifabutin

3) By Aminoglycoside: Amikacin; Streptomycin

4) By Other Drug Classes: Ethambutol; Clofazimine; Linezolid

What Key Trends Are Driving Growth In The Nontuberculous Mycobacterial Infection Market?

Prominent businesses active in the nontuberculous mycobacterial infection arena are embracing fresh approval techniques like the fast track system to maintain their market standing. This method, endorsed by the FDA, seeks to accelerate the creation and examination of medications for serious diseases with an insufficient number of treatment options. For example, in July 2022, Fast Track Designation was granted to NUZYRA for the treatment of nontuberculous mycobacterial (NTM) lung disease instigated by Mycobacterium avium complex (MAC) by the Food and Drug Administration, a federal agency based in the U.S. NUZYRA (omadacycline) is an innovative broad-spectrum antibiotic created to battle intense bacterial infections, including ones provoked by resilient strains. This designation offers a quicker progression and evaluation process for NUZYRA antibiotic to address notable medical gaps.

Which Companies Hold A Competitive Edge In The 691 Market?

Major companies operating in the nontuberculous mycobacterial infection market are Pfizer Inc., Johnson & Johnson, F. Hoffman La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Vertex Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Horizon Therapeutics PLC, Lupin Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/nontuberculous-mycobacterial-infection-global-market-report

Which Region Dominates The Nontuberculous Mycobacterial Infection Market Today?

North America was the largest region in the nontuberculous mycobacterial infection market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in nontuberculous mycobacterial infection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=13020&type=smp

Browse Through More Reports Similar to the Global Nontuberculous Mycobacterial Infection Market 2025, By The Business Research Company

Tuberculosis Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/tuberculosis-diagnostics-global-market-report

Cough And Cold Preparations Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cough-and-cold-preparations-global-market-report

Chronic Cough Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-cough-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model